VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,588,200 | -48.1% | 90,000 | -49.2% | 1.49% | -29.4% |
| Q2 2023 | $8,839,380 | +33.2% | 177,000 | 0.0% | 2.11% | +6.4% |
| Q1 2023 | $6,633,960 | -21.8% | 177,000 | 0.0% | 1.99% | -32.7% |
| Q4 2022 | $8,487,150 | +86.1% | 177,000 | -6.8% | 2.95% | +56.7% |
| Q3 2022 | $4,560,000 | +10.3% | 190,000 | 0.0% | 1.88% | +1.1% |
| Q2 2022 | $4,134,000 | -18.9% | 190,000 | -10.0% | 1.86% | +17.7% |
| Q1 2022 | $5,096,000 | -32.2% | 211,000 | -33.2% | 1.58% | -0.6% |
| Q4 2021 | $7,513,000 | -16.2% | 315,800 | -10.6% | 1.59% | -4.9% |
| Q3 2021 | $8,966,000 | +11.3% | 353,400 | -1.2% | 1.68% | +25.2% |
| Q2 2021 | $8,054,000 | +14.0% | 357,800 | 0.0% | 1.34% | +28.9% |
| Q1 2021 | $7,067,000 | -20.6% | 357,800 | +6.7% | 1.04% | -10.7% |
| Q4 2020 | $8,906,000 | -42.4% | 335,200 | +7.1% | 1.16% | -61.5% |
| Q3 2020 | $15,456,000 | – | 313,000 | – | 3.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |